Parasite
Chagas Disease
search
Chagas Disease
, American Trypanosomiasis, Trypanosoma cruzi, Rowana's Sign
See Also
Parasitic Infection
Vector Borne Disease
Immigrant Child
Refugee Health Exam
Epidemiology
Endemic Regions (tropical Americas)
Mexico
Central America
South America
Prevalence
(estimated)
Endemic regions: 8-11 Million infected
United States: 300,000 infected
Most cases are via immigration and travel
However vector-borne transmission has occurred in Southern U.S.
Bern (2011) Clin Microbiol Rev 24(4): 655-81 [PubMed]
Pathophysiology
Organism
Parasite
: Trypanosoma cruzi
Transmission: Vector borne (primary source)
Triatomine bug (reduviid bug, assassin bug or kissing bug) is an
Insect
that feeds on blood
Triatomine bugs nest in the crevices of mud and clay houses
Triatomine bugs are nocturnal and feed on humans as they sleep
Acquires T. cruzi via ingested blood containing the
Parasite
as trypomastigote
Trypomastigotes differentiate inside the
Insect
midgut into epimastigotes which further multiply
Epimastigotes differentiate into the infective form, metacyclic trypomastigotes
Insect
carrying the
Parasite
defecates into a human wound site or mucous membranes (e.g.
Conjunctiva
)
Parasite
is initially transmitted from
Insect
to human as metacyclic trypomastigote
Metacyclic trypomastigotes differentiate into amastigotes on human cell penetration
Amastigotes multiply via binary fission releasing trypomastigotes to infect other human cells
Transmission: Other mechanisms
Congenital (vertical transmission)
U.S. congenital infections per year: 300
Blood Transfusion
U.S. Blood supply is screened for Trypanosoma cruzi since 2007
Organ transplant
Contaminated food
Lab exposure
Findings
Acute Phase
Lasts for 4-8 weeks after infection
Localized Edema
at the bite site
Often asymptomatic
Rowana's Sign (20-50% of acute cases)
Painless unilateral eye swelling
Non-specific febrile illness (variably present)
Malaise
Headache
Anorexia
Non-pruritic rash
Persistent
Sinus Tachycardia
Findings
Chronic Phase
Onset weeks to months after infection
Life-long infection until treated
Asymptomatic in 70-80% of cases
Serious chronic manifestations occur in 20-30% of cases
See Complications below
Complications
Cardiac
Conduction abnormalities
Apical aneurysm
Dilated Cardiomyopathy
Congestive Heart Failure
Thromboembolism
Peroicardial effusion
Gastrointestinal
Megaesophagus
Toxic Megacolon
Neurologic
Cerebrovascular Accident
risk
Infants with congenital infection (vertical transmission from mother)
Often asymptomatic
IUGR
with low birth weight in some cases
Low
APGAR Score
s at birth
Anemia
Thrombocytopenia
Hepatomegaly
Splenomegaly
Myocarditis
(rare)
Meningoencephalitis (rare)
Labs
Acute infection
Peripheral Smear
(Light Microscopy)
Peripheral blood (or anticoagulated cord blood) for trypomastigotes
Polymerase chain reaction (PCR)
Highly specific and may be positive before
Peripheral Smear
demonstrates organisms
Chronic infection
Organism counts too low in chronic disease to be detectable by
Peripheral Smear
or PCR
Serology
tests for T. cruzi
Positive on at least two different
Serologic Test
s (insufficient efficacy of any individual test)
Enzyme-linked immunosorbent assay (
ELISA
)
Immunofluorescent
Antibody
assay
Adjunctive diagnostic modalities
Echocardiogram
(for
Heart Failure
)
Electrocardiogram
(for
Arrhythmia
)
Upper endoscopy (for megaesophagus)
Diagnostics
Electrocardiogram
Obtain at time of diagnosis and as needed
Management
Antiparasitic
Protocol
Treat immediately if not contraindicated
Course of
Antiparasitic Agent
treatment is 60-90 days
Perform physical exam to evaluate for end-organ involvement
Electrocardiogram
Contraindications to
Antiparasitic
therapy
Pregnancy
Severe hepatic insufficiency
Severe
Renal Insufficiency
Indications: Acute Chagas Disease
Treat all acute Chagas Disease cases (if not contraindicated)
Treat congenitally acquired Chagas Disease
Treat
Immunocompromised
patients with reactivated Chagas Disease
Indications: Chronic Chagas Disease
All patients under age 18 years old with chronic Chagas Disease
Patients under age 50 years old with chronic Chagas Disease and no advanced
Cardiomyopathy
Patients over age 50 years have had longterm infection that is unlikely to be cured with medication
Consult CDC or infectious disease for management recommendations regarding specific case management
Preparations (available in U.S. through CDC)
Contraindications (see above)
Pregnancy and
Lactation
Severe renal dysfunction
Severe liver dysfunction
Only two agents have proven efficacy
Benznidazole
FDA approved for ages 2-12 years old
Nifurtimox (Lampit)
FDA approved from birth to 18 years (weight >5 lb 8 oz or 2.5 kg)
Adverse effects from treatment agents
Weight loss
Anorexia
Polyneuropathy
or
Peripheral Neuropathy
Rash
Nausea
Management
Complications
Congestive Heart Failure
See
Congestive Heart Failure Exacerbation Management
Exercise
caution with
Beta Blocker
s (higher risk of
Bradycardia
)
Atrial Arrythmias
Cardiac
Pacemaker
(
Heart Block
,
Sick Sinus Syndrome
)
Ventricular
Arrhythmia
s
Amiodarone
Catheter ablation and placement of IACD
Thromboembolism
risk
Consider antithrombotic therapy
Screening
U.S.
Immigrant
s from Mexico, Central America or South America
Children of mothers with Chagas Disease
Blood donors in U.S.
Prevention
Blood donors in the United States are screened for T cruzi (since 2007)
Not allowed to donate blood if positive
Endemic area strategies
Clean rooms
Mosquito
nets
Insecticide
s
Resources
CDC Trypanosomiasis
http://www.cdc.gov/parasites/chagas/
References
Wang and Nguyen (2017) Crit Dec Emerg Med 31(9):13-8
Bern (2007) JAMA 298(18): 2171-81 [PubMed]
Cantey (2021) Am Fam Physician 104(3): 277-87 [PubMed]
Rassi (2010) Lancet 375(9723): 1388-1402 [PubMed]
Woodhall (2014) Am Fam Physician 89(10): 803-11 [PubMed]
Type your search phrase here